Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Early fallopian tube cell changes were found in a high‑risk patient. A live tissue bank and organoid system will help explore ...